Tumor and host characteristics of small cell lung cancer (SCLC) in U.S. community oncology practice

por Richards, Donald, Li, Si G, Anderson, Thomas, Monte, Marc, Ulrich, Brian, Smith, David A, Seetharam, Mahesh, Kaywin, Paul, Page, Ray, Kulig, Kimary, Batenchuk, Cory, Hussein, Maen
Publicado 2015

Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Ran...

por Hussein, Maen, Maglakelidze, Marina, Richards, Donald A, Sabatini, Marielle, Gersten, Todd A, Lerro, Keith, Sinielnikov, Ivan, Spira, Alexander, Pritchett, Yili, Antal, Joyce M, Malik, Rajesh, Beck, J Thaddeus
Publicado 2021

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

por Hart, Lowell L., Ferrarotto, Renata, Andric, Zoran G., Beck, J. Thaddeus, Subramanian, Janakiraman, Radosavljevic, Davorin Z., Zaric, Bojan, Hanna, Wahid T., Aljumaily, Raid, Owonikoko, Taofeek K., Verhoeven, Didier, Xiao, Jie, Morris, Shannon R., Antal, Joyce M., Hussein, Maen A.
Publicado 2020

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study

por Johnson, Melissa L., Cho, Byoung Chul, Luft, Alexander, Alatorre-Alexander, Jorge, Geater, Sarayut Lucien, Laktionov, Konstantin, Kim, Sang-We, Ursol, Grygorii, Hussein, Maen, Lim, Farah Louise, Yang, Cheng-Ta, Araujo, Luiz Henrique, Saito, Haruhiro, Reinmuth, Niels, Shi, Xiaojin, Poole, Lynne, Peters, Solange, Garon, Edward B., Mok, Tony
Publicado 2023

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153

por Waterhouse, David M., Garon, Edward B., Chandler, Jason, McCleod, Michael, Hussein, Maen, Jotte, Robert, Horn, Leora, Daniel, Davey B., Keogh, George, Creelan, Ben, Einhorn, Lawrence H., Baker, Justin, Kasbari, Samer, Nikolinakos, Petros, Babu, Sunil, Couture, Felix, Leighl, Natasha B., Reynolds, Craig, Blumenschein, George, Gunuganti, Vijay, Li, Ang, Aanur, Nivedita, Spigel, David R.
Publicado 2020

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

por Bendell, Johanna C., Sauri, Tamara, Gracián, Antonio Cubillo, Alvarez, Rafael, López‐López, Carlos, García‐Alfonso, Pilar, Hussein, Maen, Miron, Maria‐Luisa Limon, Cervantes, Andrés, Montagut, Clara, Vivas, Cristina Santos, Bessudo, Alberto, Plezia, Patricia, Moons, Veerle, Andel, Johannes, Bennouna, Jaafar, van der Westhuizen, Andre, Samuel, Leslie, Rossomanno, Simona, Boetsch, Christophe, Lahr, Angelika, Franjkovic, Izolda, Heil, Florian, Lechner, Katharina, Krieter, Oliver, Hurwitz, Herbert
Publicado 2019

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

por Cascone, Tina, Kar, Gozde, Spicer, Jonathan D., García-Campelo, Rosario, Weder, Walter, Daniel, Davey B., Spigel, David R., Hussein, Maen, Mazieres, Julien, Oliveira, Julio, Yau, Edwin H., Spira, Alexander I., Anagnostou, Valsamo, Mager, Raymond, Hamid, Oday, Cheng, Lin-Yang, Zheng, Ying, Blando, Jorge, Tan, Tze Heng, Surace, Michael, Rodriguez-Canales, Jaime, Gopalakrishnan, Vancheswaran, Sellman, Bret R., Grenga, Italia, Soo-Hoo, Yee, Kumar, Rakesh, McGrath, Lara, Forde, Patrick M.
Publicado 2023